HR-positive metastatic breast cancer after CDK4/6 inhibitors

What changed: HR-positive metastatic breast cancer after CDK4/6 inhibitors

Cancer page →

Every dated change on the records linked to HR-positive metastatic breast cancer after CDK4/6 inhibitors, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result13Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHR-positive metastatic breast cancer after CDK4/6 inhibitors
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026MilestoneVepdegestrant
Vepdegestrant, the first PROTAC, approved
A milestone in how this cancer is treated.

2025 · 3

2024 · 4

2023 · 3

2022 · 2

2021 · 1

2021Trial resultEMERALD
EMERALD reported
PFS HR 0.

2019 · 1

2019MilestoneSOLAR-1
Alpelisib approved for PIK3CA-mutant disease (SOLAR-1)
A milestone in how this cancer is treated.

2018 · 2

2017 · 1

2017Trial resultOlympiAD
OlympiAD reported
PFS 7.

2013 · 1

2013MilestoneHR-positive metastatic breast cancer after CDK4/6 inhibitors
ESR1 ligand-binding domain mutations found as the cause of acquired endocrine resistance
A milestone in how this cancer is treated.

2012 · 1

2012MilestoneEverolimus
BOLERO-2: everolimus with exemestane after an aromatase inhibitor
A milestone in how this cancer is treated.